What's Happening?
Sonire Therapeutics, a U.S.-based clinical-stage medical device company, has been awarded $13 million through Japan's New Energy and Industrial Technology Development Organization (NEDO) Deep-Tech Startups Support Program. This funding is aimed at advancing
the global commercialization of Sonire's High-Intensity Focused Ultrasound (HIFU) therapy platform, which is designed for non-invasive treatment of solid tumors, starting with pancreatic cancer. The funding will support manufacturing scale-up, regulatory approval activities in Japan, and the expansion of clinical indications. Sonire's HIFU system uses real-time ultrasound guidance to deliver precise tumor ablation, reducing procedural burdens and expanding access to outpatient pancreatic cancer treatment.
Why It's Important?
The funding from NEDO is significant as it supports Sonire's efforts to bring innovative cancer treatments to market, particularly for pancreatic cancer, which has a low five-year survival rate of approximately 13%. By facilitating the development and commercialization of non-invasive treatment options, this initiative could improve patient outcomes and accessibility to advanced cancer therapies. The support from a major government-backed program underscores the potential impact of Sonire's technology in transforming oncology treatment paradigms, both in Japan and the U.S.
What's Next?
Sonire plans to use the NEDO funding to accelerate its clinical development and regulatory activities, aiming for broader market adoption of its HIFU technology. The company is also focused on expanding its clinical trials and obtaining necessary approvals to make the treatment widely available. As the company progresses, it may seek further collaborations and partnerships to enhance its market reach and technological advancements.
